Immune checkpoint inhibitor agent administered by malignancy type

No. (%)
Checkpoint inhibitorMelanoman = 120Solid tumorn = 148Hematologic cancern = 59P
Ipilimumab81 (68)44 (30)13 (22)< 0.001
Nivolumab7 (6)62 (42)31 (53)
Pembrolizumab23 (19)31 (21)15 (25)
Combinationa9 (8)10 (7)0 (0)
Atezolizumab0 (0)1 (1)0 (0)

aCombination therapy consisted of ipilimumab + nivolumab